65,437 trials
Rectal Cancer
Primary: Percentage of Participants With Tumor Sterilization Defined by ypT0-N0 — 23.8; 11.4 percentage of participants — p=0.015
End Stage Renal Disease
Primary: Mean Systolic Blood Pressure Over the Third Month of Each Treatment Arm — 139; 142 mm Hg
Fracture of Cervical Spine
Primary: Adverse Events — 1 Adverse event
Osteoporosis, Osteopenia
Primary: Percentage of Change in Trabecular Surface-to-curve Ratio — 9.1; 7.1 Percentage of Change
Anesthesia
Primary: Number of Patients With Complete Sensory Block — 91; 79 percentage of participants — p=<0.01
Psoriasis
Primary: Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75) — 0; 13; 25; 57…
Influenza
Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants
Chronic Pain
Primary: Change in Pain Intensity for Overall Pain From Pre-treatment Baseline — 7.4; 3.9; 4.5; 4.7 units on a scale
Cannabis Toxicology
Primary: Delta-9-tetrahydrocannabinol (THC) Cmax in Blood — 1.4; 3.07; 0.5 ng/mL
Musculoskeletal Injury
Primary: Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm — 33.0; 29.3; 29.9 Percentage of participants — p=0.81
Atrial Fibrillation
Primary: Number of ATA (Atrial Tachyarrhythmias) Episodes and Burden, Determined at Defined Postoperative Intervals — 20,878; 1,034 ATA episodes
Lean · Obese · Obese Diabetics
Primary: Leptin Signaling — 3.1 fold change
Marijuana Smoking
Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Activity Against Neisseria Meningitidis Serogroups A, C (rSBA-MenA, C) Using Rabbit Complement Antibodies — 116; 66; 192; 53…